HROGas03 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Gastric cancer cell lines |
| Organism |
Human |
| Donor History |
Gastric adenocarcinoma |
| Growth Properties |
Adherent/Suspension |
| Growth Conditions |
Culture medium: DMEM:Ham's F12 (1:1) ,w: 3.1 g/L Glucose ,w: 2.5 mM L-Glutamine ,w: 15 mM HEPES ,w: 0.5 mM Sodium pyruvate ,w: 1.2 g/L NaHCO3 (Cytion article number 820400a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium ,we use 50% basal medium + 40% FBS + 10% DMSO ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
The HROGas03 cell line is derived from the gastric adenocarcinoma of an adult female patient. Gastric adenocarcinoma, a common type of stomach cancer, arises from the glandular epithelial cells of the stomach lining and is often associated with poor prognosis. As a model, HROGas03 provides an invaluable resource for studying the molecular pathways involved in the initiation, progression, and therapeutic resistance of gastric adenocarcinoma. The age-related aspects of the donor, such as potential genomic instability and alterations in tumor microenvironment, can provide unique insights into cancer biology in older individuals.
This cell line allows researchers to explore key molecular mechanisms driving gastric cancer, such as mutations in tumor suppressor genes (e.g., TP53), alterations in the cell cycle, and dysregulated signaling pathways, including the Wnt, MAPK, and PI3K/AKT pathways. These pathways are often implicated in the survival, proliferation, and metastatic potential of gastric cancer cells. The HROGas03 cell line can also be used to assess the efficacy of targeted therapies, chemotherapeutic agents, or combination treatments, potentially leading to improved therapeutic strategies for gastric cancer patients, especially in older demographics.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

